The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: A systematic review and meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3543-3550

  Elraiyah, Tarig ^a   Sonbol, Mohamad Bassam ^a,b   Wang, Zhen ^a   Khairalseed, Tagwa ^a   Asi, Noor ^a   Undavalli, Chaitanya ^a   Nabhan, Mohammad ^a   Firwana, Belal ^a   Altayar, Osama ^a   Prokop, Larry ^a   Montori, Victor M ^a   Murad, Mohammad Hassan ^a  

^a MAYO CLINIC   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METHYLTESTOSTERONE; PLACEBO; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL; ANDROGEN;

ACNE; ADRENAL FUNCTION; ALOPECIA; ANDROGEN THERAPY; ANTHROPOMETRY; BODY COMPOSITION; BODY WEIGHT DISORDER; BONE DENSITY; DISEASE ASSOCIATION; DISTRESS SYNDROME; FEMALE; FOLLOW UP; HIRSUTISM; HUMAN; HYPOALPHALIPOPROTEINEMIA; HYPOCHOLESTEROLEMIA; INCIDENCE; LIPID BLOOD LEVEL; META ANALYSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SEXUAL FUNCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOICE CHANGE; VOICE DISORDER; WEIGHT GAIN; ADRENAL GLAND; AGING; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; SEXUALITY;

ADRENAL GLANDS; AGING; ANDROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUALITY; TESTOSTERONE;

EID: 84907668716     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2262     Document Type: Review

References (30)

1. De Gendt K, Verhoeven G. Tissue- and cell-specific functions of the androgen receptor revealed through conditional knockout models in mice. Mol Cell Endocrinol. 2012;352:13-25.
2. Arlt W. Androgen therapy in women. Eur J Endocrinol. 2006;154:1-11.
3. Bancroft J. Sexual effects of androgens in women: some theoretical considerations. Fertil Steril. 2002;77(suppl 4):S55-S59.
4. Sarrel PM. Psychosexual effects of menopause: role of androgens. Am J Obstet Gynecol. 1999;180:S319-S324.
5. Ebinger M, Sievers C, Ivan D, Schneider HJ, Stalla GK. Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression? J Psychopharmacol. 2009;23:841-853.
6. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab. 1995;80:1429-1430.
7. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2012;9:1134-1148.
8. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Mühlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2000;85:645-651.
9. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med. 2008;168:1441-1449.
10. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21:227-236.
11. Burger H, Hailes J, Nelson J, Menelaus M. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br Med J (Clin Res Ed). 1987;294:936-937.
12. Burger HG, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N. The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas. 1984;6:351-358.
13. Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010;13:121-131.
14. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359:2005-2017.
15. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343:682-688.
16. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 2008;61:17-26.
17. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipidlipoprotein profiles in surgical menopause. Obstet Gynecol. 1995;85:529-537.
18. Barrett-Connor E, Young R, Notelovitz M, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med. 1999;44:1012-1020.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
20. Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. doi:10.1002/14651858.CD004509.pub2. 2006;91:3697-3710.
21. Somboonporn W, Bell RJ, Davis SR. Testosterone for peri and postmenopausal women (Review) [published online April 17, 2007]. Cochrane Database Syst Rev. 2009;3.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
23. Higgins JP, Altman DG. Assessing risk of biasin included studies. In: Higgins JP, Altman DG, eds. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: John Wiley, Sons, Ltd; 2008:187-241.
24. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666-673.
25. der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
26. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006;333:597-600.
27. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological). 1995;57:289-300.
29. Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric. 2008;11:181-191.
30. Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril. 2007;88:1-17.